...Thanks, Rahul. We're really excited to be taking part at the conference today. For those that are not familiar with the Phathom story, we intend to walk through a very short corporate deck for the first 15 minutes, and then we'll open it up to Q&A for the last section of the program. So I'll be referring to a deck throughout the presentation that was distributed and referring to page numbers just so you can track along. So Phathom was formed in 2019, and we've licensed vonoprazan, which is a potassium competitive acid blocker or P-CAB for the US, Canada and for Europe. And we believe vonoprazan has the potential to be a blockbuster, a first-in-class, best-in-class acid suppression therapy in a category where there hasn't been any innovation in over 25 years. Vonoprazan has established a track record. It's already available in 14 countries. And so it's largely derisked from both a clinical as well as a commercial perspective. In Japan, it's delivering revenue of more than $800 million and...
